0001209191-19-047178.txt : 20190822 0001209191-19-047178.hdr.sgml : 20190822 20190822192004 ACCESSION NUMBER: 0001209191-19-047178 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190821 FILED AS OF DATE: 20190822 DATE AS OF CHANGE: 20190822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mahatme Sandesh CENTRAL INDEX KEY: 0001511034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 191046901 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-21 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001511034 Mahatme Sandesh 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 0 1 0 0 EVP, CFO & CBO Common Stock 2019-08-21 4 M 0 100000 23.85 A 130179 D Common Stock 2019-08-21 4 F 0 57465 101.50 D 72714 D Common Stock 2019-08-22 5 G 0 E 42535 0.00 D 30179 D Common Stock 12012 I By trust Stock Appreciation Right 23.85 2019-08-21 4 M 0 100000 0.00 D 2022-11-05 Common Stock 100000 0 D This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes. This transaction involved a gift of shares of common stock by the reporting person to a family trust. 25% of the shares subject to the SAR vested on the first anniversary measured from November 5, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vested in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the SAR were fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme 2019-08-22